Arrowhead FQ2 top line down 51%; COVID-19 program started

Arrowhead Pharmaceuticals (NASDAQ:ARWR) fiscal Q2 results:

Revenue: $23.5M (-51.1%).

Net loss: ($19.8M); loss/share: ($0.20).

Development program in COVID-19 underway (no additional details disclosed).

Arrowhead Pharmaceuticals EPS misses by $0.09, beats on revenue

https://seekingalpha.com/news/3571471-arrowhead-fq2-top-line-down-51-covidminus-19-program-started

Herbalife posts healthy increase in adjusted earnings; cash flow ops up 268%

Herbalife Nutrition (NYSE:HLF) Q1 results:

Sales: $1,262.4M (+7.7%).

Net income: $45.6M (-52.6%); non-GAAP net income: $116.3M (+24.5%); EPS: $0.32 (-51.5%); non-GAAP EPS: $0.83 (+25.8%).

Cash flow ops: $141.7M (+268.1%).

Volume points: Total: 1,563.5M (+5.6%); Asia Pacific: 409.7M (+11.0%); North America: 356.0M (+7.7%); EMEA: 336.7M (+3.4%); Mexico: 209.8M (-6.7%); South/Central America: 126.7M (-5.3%); China: 124.6M (+29.4%).

Preliminary volume points in April: Total: 506.9M (-0.7%).

Company unable to provide 2020 guidance due to pandemic disruptions.

Shares up 1% after hours.

Herbalife EPS beats by $0.22, revenue in-line

https://seekingalpha.com/news/3571569-herbalife-posts-healthy-increase-in-adjusted-earnings-cash-flow-ops-up-268

Puma Biotechnology EPS beats by $0.48, beats on revenue

Puma Biotechnology (NASDAQ:PBYI): Q1 Non-GAAP EPS of -$0.20 beats by $0.48; GAAP EPS of -$0.43 beats by $0.34.

Revenue of $51.2M (-48.3% Y/Y) beats by $6.78M.

Shares +8.81%.

Press Release

https://seekingalpha.com/news/3571570-puma-biotechnology-eps-beats-0_48-beats-on-revenue

Allscripts Healthcare Solutions EPS misses by $0.06, misses on revenue

Allscripts Healthcare Solutions (NASDAQ:MDRX): Q1 Non-GAAP EPS of $0.09 misses by $0.06; GAAP EPS of -$0.13 misses by $0.07.

Revenue of $417M (-3.6% Y/Y) misses by $4.14M.

Press Release

https://seekingalpha.com/news/3571596-allscripts-healthcare-solutions-eps-misses-0_06-misses-on-revenue

La Jolla Pharma makes a run at Tetraphase Pharma

TetraPhase Pharmaceuticals (NASDAQ:TTPH) discloses that it has received an unsolicited bid from La Jolla Pharmaceutical Company (NASDAQ:LJPC) consisting of $22M in cash and an additional $12.5M payable via a contingent value right (CVR). The board is considering the offer.

On March 26, it agreed to be acquired by AcelRx Pharmaceuticals (NASDAQ:ACRX) for ~$14.4M in an all-stock deal.

https://seekingalpha.com/news/3570959-la-jolla-pharma-makes-run-tetraphase-pharma

Teva posts strong Q1, cash flow ops up 172%

Teva Pharmaceutical Industries (NYSE:TEVA) Q1 results:

Revenues: $4,357M (+5.0%).

Generics: $2,433M (+4.6%); Anda: $426M (+12.4%); Copaxone: $319M (-4.8%); Austedo: $122M (+64.9%); Bendeka/Treanda: $105M (-13.9%); Ajovy: $33M (+65.0%).

Net income: $69M (+165.7%); non-GAAP net income: $835M(+27.7%); EPS: $0.06 (+160.0%); non-GAAP EPS: $0.76 (+26.7%).

Cash flow ops: $305M (+172.3%).

Teva Pharmaceutical EPS beats by $0.17, beats on revenue

https://seekingalpha.com/news/3571074-teva-posts-strong-q1-cash-flow-ops-up-172

Moderna cleared for Phase 2 study of COVID-19 vaccine

Alongside Q1 results, Moderna (NASDAQ:MRNA) says the FDA has given the green light to begin the Phase 2 study on its novel coronavirus vaccine (mRNA-1273).

It’s expected to start imminently, with the goal of a Phase 3 study to begin in early summer, and approval as soon as 2021.

https://seekingalpha.com/news/3571075-moderna-cleared-for-phase-2-study-of-covidminus-19-vaccine